Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Atea Pharmaceuticals Inc
Healthcare
P/NCAV
0.56x
Ticker
AVIR
Exchange
NASDAQ
Country
United States
Close
3.73 $
Mkt Cap
311.0M $
EV
167.2M $
NCAV Burn Rate
13.2%
Current Ratio
18.24
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-1.0x
EV/FCF
-2.0x
Dilution
0.6% p.A
Total Net Income
-164.7M $
Cheapness
100.0%
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average